Background: Data are limited on risk factors for vancomycin-resistant Enterococcus (VRE) bacteremia. Methods: All patients with a confirmed VRE bacteremia in Ontario, Canada, between January 2009 and December 2013 were linked to provincial healthcare administrative data sources and frequency matched to 3 controls based on age, sex, and aggregated diagnosis group. Associations between predictors and VRE bacteremia were estimated by generalized estimating equations and summarized using odds ratios (ORs) and corresponding 95% confidence intervals (CIs). Results: In total, 217 cases and 651 controls were examined. In adjusted analyses, patient-level predictors included bone marrow transplant ]); solid organ transplant (OR 17.17 [95% CI 4.95-59.54]); any cancer (OR 8.64 [95% CI 3.88-19.21]); intensive care unit (ICU) admission (OR 6.81 [95% CI 3.53-13.13]); heart disease (OR 5.27 [95% CI 2.00-13.90]); and longer length of stay (OR 1.07 per day [95% CI 1.06-1.09]). Hospital-level predictors included hospital size (per increase in 100 beds (OR 1.26 [95% CI 1.07-1.48]) and teaching hospitals (OR 3.87 [95% CI 1.85-8.08]). Conclusions: Patients with a bone marrow transplant, solid organ transplant, cancer, or who are admitted to the ICU are at highest risk of VRE bacteremia, particularly at large hospitals and teaching hospitals. Crown This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). (VRE) is an important healthcare-associated antibiotic-resistant organism. 1-3 In a previous systematic review and meta-analysis, we showed that patients who develop VRE bacteremia have higher associated risk of mortality and longer length of stay than patients with vancomycinsusceptible Enterococcus (VSE) bacteremia. 4 Having a better understanding of those at highest risk of developing VRE bacteremia as well as those at highest risk of dying from VRE bacteremia may help inform clinical practice and infection prevention and control policies.
study. Furthermore, many studies were performed in specific immunocompromised populations. 11, [15] [16] [17] Although these studies provide insight into risk factors within these at-risk groups, they do not allow direct comparison of risk estimates between different risk groups. Moreover, many of the studies were performed prior to the widespread use of anti-VRE therapy, which may have affected the epidemiology. 6, [9] [10] [11] 13, 15, 17, 18 The purpose of this study was to determine patient-and hospitallevel predictors of VRE bacteremia in Ontario, Canada, by performing a population-based, case-control study. Predictors of mortality among patients with VRE bacteremia were also sought.
METHODS

Study design
We performed a population-based, case-control study of all inhospital adult patients diagnosed with a VRE bacteremia between January 1, 2009, and December 31, 2013 . Each patient with a VRE bacteremia was frequency matched, in a 1:3 ratio, 19 to in-hospital patients without VRE bacteremia based on age, sex, and aggregated diagnosis group (ADG) (The Johns Hopkins ACG System, Version 10.0). 20, 21 Controls were hospitalized during the same time period as the VRE bacteremia cases (restricted to be within 1 week pre/post from the VRE index date).
Case ascertainment
Since January 2009, all 219 hospitals in Ontario have been mandated to publicly report their VRE bacteremias quarterly, using the Ontario Ministry of Health and Long-Term Care's case definition for a VRE bacteremia. 22, 23 Briefly, VRE bacteremia is defined as a single positive blood culture growing Enterococcus faecium or Enterococcus faecalis that has a minimum inhibitory concentration to vancomycin of ≥ 32 mcg/ml. 22, 23 Study investigators validated the publicly reported data 24 by contacting infection prevention and control professionals at each hospital site to confirm whether the reported VRE bacteremia met the case definition. Patients with a confirmed VRE bacteremia were included in the study.
Data sources
The study was completed using provincial healthcare administrative databases linked via unique encoded identifiers and analyzed at the Institute for Clinical Evaluative Sciences (ICES). ICES is a publicly funded, not-for-profit research institute in Ontario, Canada. ICES maintains a data repository comprised of record-level, coded, and linkable health datasets. Currently, the repository includes health service records for as many as 13 million people. Data were obtained using health administrative databases, which included patientlevel data on age, sex, comorbidities, intensive care unit (ICU) admission, length of stay, mortality, and facility-level data on bed size and facility type. Specifically, we obtained hospital length of stay and ICU admission from the Canadian Institute for Health Information Discharge Abstract Database (DAD). The Charlson index 25, 26 and ADG score were calculated based on International Classification of Diseases-10 diagnostic codes from the DAD and Ontario Health Insurance Plan Claims Database. Demographic information including age, sex, and date of death was obtained using the Registered Persons Database Files. To determine comorbidities, we used validated disease-specific registries and established algorithms, including the Ontario Congestive Heart Failure Dataset, 27 the Ontario Chronic Obstructive Pulmonary Disease (COPD) Dataset, 28 the Ontario Diabetes Dataset, 29 the Canadian Organ Replacement Registry, and the Ontario Cancer Registry. 30 A 2-year timeframe was used for the following comorbidities: cancer, heart disease, diabetes, and COPD. No time restriction was applied to solid organ transplant. Hospital size and hospital type were obtained using the Ministry of Health and Long-Term Care and Levels of Care Classification System datasets.
Ethics
This study obtained Research Ethics Board approval from Public Health Ontario, Sunnybrook Health Sciences Centre (ICES Central), and from each participating hospital site.
Statistical analysis
Baseline demographics, clinical characteristics, and outcomes of cases and controls were summarized as mean and standard deviation or median and interquartile range (IQR) for continuous variables and percentages for categorical variables. T-test, Wilcoxon ranksum test, Fisher's exact test, or χ2 test were used for comparison, as appropriate.
The associations between patient-and hospital-level predictors and VRE bacteremia were estimated by generalized estimating equations (to control for clustering at the hospital level) and summarized as unadjusted and adjusted odds ratios (ORs) (adjusted for age as a continuous variable; sex; Charlson score [0, 1, and ≥2]; ICU admission; length of hospital stay in days as a continuous variable; history of cancer, diabetes, COPD, cardiac disease, or solid organ transplant; hospital size [bed-size re-scaled by dividing by 100 and analyzed as a continuous variable] and hospital type [teaching versus community]) and corresponding 95% confidence intervals (CIs). In the event a patient developed VRE bacteremia more than once in the study period, only the first VRE bacteremia was included.
The associations between patient-level predictors of 30-day mortality among patients with VRE bacteremia were estimated by logistic regression and summarized as unadjusted and adjusted OR (adjusted for age as a continuous variable; sex; Charlson score [0, 1, and ≥2]; length of stay; ICU admission; history of cancer, diabetes, COPD, cardiac disease, or solid organ transplant) and corresponding 95% CIs. Attribution of mortality to VRE bacteremia was not assessed.
All P-values were 2 sided, and the significance level was set at .05. Analyses were performed using SAS software (version 9.3; SAS, Cary, North Carolina).
RESULTS
In total, 286 VRE bacteremias were publicly reported by hospitals during the study period. Of these, 232 patients had a confirmed VRE bacteremia during the study period; 217 cases were successfully linked to the administrative data sources and matched to 651 controls (Fig 1) . Cases and controls were frequency matched based on age, sex, and ADG score. No significant differences were observed in age, sex, or ADG variables between the 2 groups (Table 1) . However, the proportion of comorbidities in cases was greater compared to controls, as measured by the Charlson comorbidity index, and for each of the comorbidities measured (P < .01 for each) ( Table 1 ). The overall length of stay for cases was longer than controls (median 39 days [IQR 22-81 days] vs median 3 days [IQR 1-6 days], P < .0001), and 40% (86/217) of cases died within 30 days versus 4% (23/651) of controls (P < .0001) ( Table 1 ). Cases were more commonly from teaching hospitals than controls (76% [165/217] vs 28.5% [186/651], P < .001).
Unadjusted patient-and hospital-level predictors of VRE bacteremia can be found in (Table 3) .
DISCUSSION
In this large, multicenter, province-wide, population-based study investigating patient-and hospital-level predictors of VRE bacteremia, we found that patients with a history of bone marrow transplant and solid organ transplant were at highest risk of VRE bacteremia, as were those with cancer and those who were admitted to the ICU, particularly at large hospitals and teaching centers. Forty percent of patients with VRE bacteremia died within 30 days of a VRE bacteremia diagnosis, and admission to the ICU was the most important predictor of mortality.
In this case-control study, a history of bone marrow transplantation was the most significant predictor of VRE bacteremia, which is consistent with previous studies. 5, 6 It is hypothesized that the risk could be related to the immunosuppression from neutropenia (also previously described as a risk factor 5, 9 ) , mucositis, 31 chemotherapy, or the nature of the medical care for the underlying disease. 5, 16 The presence of a central venous catheter could also contribute to the increased risk. 5 A cancer history remained a significant predictor of VRE bacteremia, even when patients with bone marrow transplantation were excluded, albeit at a lower risk than patients undergoing bone marrow transplantation, potentially reflecting differing degrees of immunosuppression. Solid organ transplantation was also a very significant predictor of VRE bacteremia, which could also relate to immunosuppression. 32 Patients admitted to the ICU were also at increased risk of VRE bacteremia when compared to controls. This could relate to the severity of illness in patients in the ICU, as increasing APACHE score has been shown to be associated with higher VRE bacteremia risk. 6, 33 Alternatively, the risk could be explained by the presence of central venous catheters 5 and other invasive procedures, which are commonly used in the ICU setting. 34 Antimicrobial use is also higher in the ICU setting, in particular vancomycin, potentially leading to the selection of VRE as a pathogen among ICU admitted patients. 35 Increasing length of stay was a predictor of VRE bacteremia. We hypothesize that the association relates to the increased risk of VRE colonization in patients with longer lengths of stay 36 ; alternatively, it could relate to an unmeasured confounder such as frailty differences between the cases and controls, as frailty is associated with increased length of stay. 37
Fig 1. Flow diagram
When hospital predictors of VRE bacteremia were investigated, patients in teaching hospitals and hospitals of increasing size were at increased risk of VRE bacteremia, even after accounting for important patient-level predictors such as age, sex, comorbidity indices, specific comorbidities, and clustering at the hospital level. We hypothesize that the increased risk could relate to the level of connectivity (eg, number of shared patients through transfers) of the hospital. 38 A hospital-level risk factor analysis of methicillinresistant Staphylococcus aureus (MRSA) bacteremia in Scotland determined that the probability of a hospital having at least 1 case of MRSA bacteremia was associated not only with size, but also with the level of connectedness of the hospital to other hospitals. 38 In our study, we were not able to determine the degree of connectedness and thus adjust for it. Future work may pursue this hypothesis. Alternatively, the difference could reflect other unmeasured confounders including VRE colonization pressure. 39 In our study, 40% of patients with VRE bacteremia died within 30 days of diagnosis. This is similar to the 52% 30-day mortality seen in a large multicenter study in the United States 18 and the 46% 28day mortality in a 10-year single-center study in Korea. 12 This mortality was all-cause mortality, and this study was not designed to ascertain if the VRE bacteremia was the attributable cause.
Nevertheless, having a better understanding of the mortality in patients with VRE bacteremia will help clinicians prognosticate and will help inform clinical decisions and discussions with patients and family. This is particularly true in patients requiring ICU admission, since this was the most significant predictor for increased mortality in patients with VRE bacteremia, which is consistent with a prior study of predictors of mortality in patients with vanB VRE bacteremia. 5 Male sex was associated with reduced risk of mortality. This association was also observed in a small study of 48 patients with VRE bacteremia, although the association between female sex and risk of mortality was not statistically significant (female sex OR 2.4 [95% CI 0.70-8.9]). 6 Two studies did not find an association between sex and mortality in patients with VRE bacteremia. 7, 12 The potential reasons for females being at increased risk for mortality in VRE bacteremia are not clear but should be explored in future studies.
Strengths of this study include 5 years of population-based surveillance in a large area and a comprehensive dataset. However, several limitations must be considered. First, since this was an observational case-control study, predictors may only represent associations and may not reflect causality. Additionally, unmeasured confounding could remain in our model. For example, we did not have knowledge of patients' residence (eg, long-term care home vs community dwelling) or nutritional status. We did not have microbiologic data or knowledge of other concomitant infections, the type of enterococcal species causing the bacteremia, or whether the presence of polymicrobial bacteremia might have influenced mortality, although previous studies have not identified such associations. 10 In addition, antibiotic therapy data were not available; vancomycin use has been shown to be a predictor of VRE bacteremia in most, but not all, previous studies. 5, 6, [8] [9] [10] [11] 33 Furthermore, other medications, such as type of chemotherapy or other immunosuppressive medications, were not known. Second, the study period ended December 31, 2013. The delay between the study period and manuscript submission reflects the complexity of the study; extensive coordination between Public Health Ontario, 45 hospital sites, and ICES was required. We think that the results are still timely and relevant. Lastly, we were unable to conduct a case-casecontrol study design, which is an approach that can be used to determine antimicrobial resistance risk factors. 40 Although we currently do not have the mechanisms to identify a VSE bacteremia cohort, this may be a possibility in the future. Currently, detailed microbiologic data across various laboratory databases are being linked in our ICES databases and offer a potential opportunity to employ this design for future studies.
The results of this study may help inform hospital infection prevention and control initiatives, as VRE control strategies may be most critical in those at highest risk of VRE bacteremia (eg, bone marrow and solid organ transplantation and ICU patients). These data may help relevant hospital programs advocate for additional resources to support enhanced surveillance of hand hygiene adherence and education, additional environmental services and support, and implementation of central line-associated bloodstream infection prevention bundles. Moreover, the results may help inform patient groups that may benefit from VRE screening programs, although this study was not designed to evaluate the effectiveness of such an approach. The data may also help inform empiric antimicrobial therapy prescribing, as clinicians may be more likely to consider empiric anti-VRE therapy in patients at highest risk of VRE bacteremia. Delays in effective antimicrobial therapy may be associated with increased risk of death in patients with VRE bacteremia. 41 In summary, patients with a bone marrow transplant, solid organ transplant, and cancer, and patients admitted to the ICU are at highest risk of VRE bacteremia, particularly at large hospitals and teaching hospitals. Furthermore, approximately 40% of patients with a VRE bacteremia will die within 30 days. These results may help inform clinical practice and infection prevention and control efforts. 
